23rd Annual Winter Lung Cancer Conference®

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities (Spotlight CE Session)

Spotting the Signal: Recognizing and Treating Paraneoplastic LEMS in Small Cell Lung Cancer (Spotlight CE Session)

Welcome and Introductions

Presession Survey

Beyond PD-L1: Next-Generation Biomarkers for Precision Immunotherapy

Overcoming the Wall: Restoring Immune Response in IO-Resistant Tumors

Beyond Checkpoint Inhibition: Expanding the Immunotherapy Arsenal

Postsession Survey

Panel Discussion & Q&A Session

Reading the Signals: Monitoring Response and Detecting Resistance with cfDNA

Minimal Residual Disease in Lung Cancer: Is Prime Time Here?

Real-World Cases and Controversies: Liquid Biopsy in Practice

Dinner

The Evolving Progress in the Management of Small Cell Lung Cancer

Discussion and Q&A

Closing Remarks and Meeting Adjournment

Welcome Reception

Breakfast

The EGFR Crossfire: Monotherapy, Intensification, and Beyond

Targeting EGFR Exon 20: Advances and Challenges

Rare but Relevant: Uncommon and PACC Mutations in Lung Cancer

Battling EGFR Resistance: Overcoming the Next Frontier

Break

Multidisciplinary Tumor Board

Lunch

Presession Survey (for Sessions 6 & 7)

Tackling KRAS: From G12C and Beyond

Tackling HER2 Mutations: Targeted Strategies in Lung Cancer

ALK and ROS1 Pathways: Optimizing Targeted Therapy

Emerging Targets: RET, NRG1, NTRK, and MET Pathways in Lung Cancer

5 Top Unanswered Questions in Stage III NSCLC--> The Roadmap to the Future

Oligometastatic NSCLC: Challenges, Dilemmas, and Clinical Decisions

Smoking Cessation

Postsession Survey (for Sessions 6 & 7)

Adjourn

Case-Based Panel: A Real-World Discussion

AI in Action: Practical Applications for Oncology Practice

Q&A Session

Medical Crossfire®: Perioperative vs Neoadjuvant Therapy—Which Path Forward?

Beyond pCR: Optimizing Care for Patients With Residual Disease

Medical Crossfire®: Will ADCs Replace Chemotherapy in First-Line NSCLC?

Two Targets, One Therapy: The Rise of Bispecifics in Lung Cancer

ADC Advances in NSCLC: Tackling cMET, TROP2 & HER2 Overexpression

ADCs in SCLC: Emerging Opportunities and Challenges